Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease. (November 2017)

• Record Type: Journal Article
• Authors: Zhang, Sudong; He, Yi; Jiang, Erlie; Wei, Jialin; Yang, Donglin; Zhang, Rongli; Zhai, Weihua; Zhang, Guixin; Wang, Zhao; Zhang, Lining; Liu, Li; Han, Mingzhe; Feng, Sizhou
• Is Part Of: Future microbiology. Volume 12:Number 15(2017)
• Page Start: 1371
• Page End: 1379
• Publication Date: 2017-11
• Subjects: hematopoietic stem cell transplantation -- invasive fungal disease -- posaconazole; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2017-0131
• Languages: English
• ISSNs: 1746-0913

Abstract

Aim: Invasive fungal disease (IFD) is a significant cause of morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients. This study reports real-world efficacy and safety of posaconazole (POS) in HSCT recipients with IFD.Patients & methods: We performed a retrospective study to investigate the efficacy and safety of POS oral suspension in 45 HSCT patients with IFD from December 2013 to December 2016.Results: The success rate at 12 weeks after POS treatment was 57.8%. Multivariate logistic regression analysis showed that persistent neutropenia, severe graft-versus-host disease, high-dose steroid and cytomegalovirus infection were independently associated with inferior responses to POS. POS caused some adverse effects of mild or moderate severity that were of short duration.Conclusion: This study provides encouraging data regarding the efficacy and safety of POS in HSCT recipients. Neutropenia, graft-versus-host disease, steroid use and cytomegalovirus infection are possibly associated with inferior responses to POS therapy.